BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)
BBS Bioactive Bone Substitutes Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Jalovaara, Pekka
Position: Member of the Board/Deputy member
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20220826100002_2
____________________________________________
Transaction date: 2022-05-23
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522818
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 55,862 Unit price: 0.0121 EUR
Aggregated transactions
(1): Volume: 55,862 Volume weighted average price: 0.0121 EUR
____________________________________________
Transaction date: 2022-05-24
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522818
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 165,492 Unit price: 0.0085 EUR
Aggregated transactions
(1): Volume: 165,492 Volume weighted average price: 0.0085 EUR
____________________________________________
Transaction date: 2022-05-25
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522818
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 4,662 Unit price: 0.006 EUR
(2): Volume: 61,786 Unit price: 0.0043 EUR
Aggregated transactions
(2): Volume: 66,448 Volume weighted average price: 0.00442 EUR
____________________________________________
Transaction date: 2022-05-27
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522818
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 142,848 Unit price: 0.0013 EUR
(2): Volume: 71,400 Unit price: 0.0013 EUR
(3): Volume: 17,850 Unit price: 0.0013 EUR
Aggregated transactions
(3): Volume: 232,098 Volume weighted average price: 0.0013 EUR
For more information:
Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi
Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi
Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.
BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information: www.bbs-artebone.fi
Why Did You Get into MedTech? Join us at DeviceTalks West to Learn from other…
Gemina Laboratories (OTCQB: GLABF), (CSE: GLAB), (FRA: 817) expands investor reach to U.S. by posting…
Technology Leaders Partner to Develop First Smartphone-Based Combined Pediatric Vision and Hearing Screening SolutionNASHVILLE, TN…
RONKONKOMA, N.Y.--(BUSINESS WIRE)--#biopharma--Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical…
RONKONKOMA, N.Y.--(BUSINESS WIRE)--#biopharma--Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical…
GE HealthCare and MediView XR, Inc. announce the first installation and clinical use of augmented…